P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.

• Stefanie Schalm,
• Yogesh Chutake,
• Susanne Breitkopf,
• Michele Mayo,
• Nancy Dumont,
• Dapeng Chen,
• Vaishali Dixit,
• Rahul Karnik,
• Alice Mcdonald,
• Jessica Filiatrault,
• William Proctor,
• Frank Qi,
• Kan-Nian Hu,
• Matt Weiss,
• Ashwin Gollerkeri,
• Kirti Sharma,
• Joseph D Growney,
• Juliet Williams

Affiliations

Stefanie Schalm

1 Kymera Therapeutics, Oncology, Watertown, United States

Yogesh Chutake

2 Kymera Therapeutics, Translational Medicines, Watertown, United States

Susanne Breitkopf

3 Kymera Therapeutics, Proteomics, Watertown, United States

Michele Mayo

4 Kymera Therapeutics, Pharmacology, Watertown, United States

Nancy Dumont

4 Kymera Therapeutics, Pharmacology, Watertown, United States

Dapeng Chen

5 Kymera Therapeutics, DMPK, Watertown, United States

Vaishali Dixit

5 Kymera Therapeutics, DMPK, Watertown, United States

Rahul Karnik

6 Kymera Therapeutics, Computational Biology, Watertown, United States

Alice Mcdonald

2 Kymera Therapeutics, Translational Medicines, Watertown, United States

Jessica Filiatrault

1 Kymera Therapeutics, Oncology, Watertown, United States

William Proctor

7 Kymera Therapeutics, Safety, Watertown, United States

Frank Qi

9 Kymera Therapeutics, CMC, Watertown, United States

Kan-Nian Hu

9 Kymera Therapeutics, CMC, Watertown, United States

Matt Weiss

10 Kymera Therapeutics, Chemistry, Watertown, United States

Ashwin Gollerkeri

11 Kymera Therapeutics, Clinical Development, Watertown, United States

Kirti Sharma

3 Kymera Therapeutics, Proteomics, Watertown, United States

Joseph D Growney

4 Kymera Therapeutics, Pharmacology, Watertown, United States

Juliet Williams

12 Kymera Therapeutics, Head of Research, Watertown, United States